Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis
Conditions
Keywords
Rheumatiod Arhthritis, Ankylosing spondylitis, Psoriatic arthritis, Biologic agents, Cohort studies, Small molecule agents
Brief summary
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the real world use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.
Detailed description
This registry is a multi-center, prospective, observational program that will gather and analyze data on patients being treated with biologics and targeted synthetic DMARDs in Korea. In contrast to a controlled clinical trial, there is no imposed experimental intervention and solely the patients' physicians will determine the patient's treatment. Thus, the data captured and reported in this registry will reflect a real world approach to the treatment with biologics or targeted synthetic DMARDs. There will be no additional visit or laboratory test done outside the routine clinical practice. The selection of the agent, dosing, and treatment duration is determined by the investigator. Informed consent will be obtained from the patient prior to the collection of any data.
Interventions
DRUGBiologic or targeted synthetic DMARD
Sponsors
Seoul National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with RA, AS or PsA * RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s) * AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD * Patients who provide a written consent of participating in this registry (data collection and review).
Exclusion criteria
* RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events during the use of biologics or targeted synthetic DMARDs in Korean patients with Rheumatic diseases | up to 10 years | Patient will be followed on a yearly basis. Adverse events based on MedDRA® during the observational period will be filled out on each follow up. Adverse events will also be assessed in the case of switching or discontinuation of biologics. |
Countries
South Korea
Contacts
Primary ContactKichul Shin, MD
Backup ContactKeunyoung O
Outcome results
None listed